441 related articles for article (PubMed ID: 26978006)
1. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
2. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
6. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.
Antonuzzo L; Del Re M; Barucca V; Spada F; Meoni G; Restante G; Danesi R; Di Costanzo F; Fazio N
Cancer Treat Rev; 2017 Jun; 57():28-35. PubMed ID: 28535439
[TBL] [Abstract][Full Text] [Related]
7. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.
Passacantilli I; Capurso G; Archibugi L; Calabretta S; Caldarola S; Loreni F; Delle Fave G; Sette C
Oncotarget; 2014 Jul; 5(14):5381-91. PubMed ID: 25026292
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
12. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
14. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
15. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
Calero R; Morchon E; Martinez-Argudo I; Serrano R
Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]